Oxytocin And Uterotonic Agent Use For Cesarean Delivery

• Status: Completed
• Trial end date: 2012-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

The central objective of this study will be to evaluate a standardized, evidence-based regimen versus a conventional regimen for uterotonic drug dosing for elective cesarean delivery

The investigators primary hypothesis is that the proposed uterotonic drug regimen, when compared to conventional dosing regimen, during elective cesarean delivery will:

1. Reduce the overall amount of oxytocin and other uterotonic agents used to obtain satisfactory uterine tone.

Secondary outcomes to be evaluated will be:

1. Reduce the side effects associated with uterotonic drug use

2. Reduce the time to establishment and maintenance of adequate uterine tone

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Brigham and Women's Hospital
• Treatments: Carboprost; Carboprost tromethamine; Maleic acid; Methylergonovine; Misoprostol; Oxytocin

Criteria

Inclusion Criteria:

• American Society of Anesthesiologists (ASA) I or II health status

• Age between 18 and 50 yrs

• Singleton pregnancies in vertex position

• Elective (without prior labor) cesarean delivery with a planned lower uterine (pfannenstiel) incision

Exclusion Criteria:

• Conditions that predispose to uterine atony and postpartum hemorrhage